What is NDC 25021-118?

25021-118 is the product NDC for Cefuroxime sodium, Cefuroxime sodium 750 mg/1 injection, powder, for solution, listed with the FDA by Sagent Pharmaceuticals. It has 1 package NDC, shown above in 10- and 11-digit form.

Sagent Pharmaceuticals, NDC labeler code 25021. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Cefuroxime sodium?

1 other product NDC are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Cefuroxime sodium NDC 25021-118 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)25021-118Labeler and product segments. Claims need a package NDC.

Product NDC at billing width25021-0118Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
25021-118-10	2502101181025021011810	25 VIAL in 1 CARTON (25021-118-10) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIALMarketed from Sep 1, 2016

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cefuroxime sodium
Generic name (nonproprietary): cefuroxime sodium
Active ingredients: Cefuroxime sodium — 750 mg/1
Dosage form: Injection, Powder, For solution
Route: Intramuscular, Intravenous
Labeler: Sagent PharmaceuticalsNDC labeler code 25021
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 064125
Marketing start: Sep 1, 2016
Listing expires: Dec 31, 2027
Other FDA classes: Cephalosporins (Chemical structure)
Identifiers: Product ID 25021-118_da170a9c-def7-432b-8999-701e7b878fe8SPL ID da170a9c-def7-432b-8999-701e7b878fe8SPL set ID 0a145288-733a-4966-b7ae-dc96eb103d8cRxCUI 1665444, 1665449UNII R8A7M9MY61
Pharmacologic class: Cephalosporin Antibacterial

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N425021011810 followed by a unit qualifier and the quantity

Package 25021-0118-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 27, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Cefuroxime for Injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections , including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non-penicillinase- producing strains), Streptococcus pyogenes , and Escherichia coli . Urinary Tract Infections caused by Escherichia coli and Klebsiella spp. Skin and Skin-Structure Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), St…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 25021-118

What is NDC 25021-118?: 25021-118 is the product NDC for Cefuroxime sodium, Cefuroxime sodium 750 mg/1 injection, powder, for solution, listed with the FDA by Sagent Pharmaceuticals. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Cefuroxime sodium.
What is the active ingredient?: Cefuroxime sodium.
Who is the labeler?: Sagent Pharmaceuticals, NDC labeler code 25021. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Cefuroxime sodium?: 1 other product NDC are listed under this name. See all Cefuroxime sodium NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Cefuroxime sodium NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Cefuroxime sodium	Cefuroxime sodium 1.5 g/20mL	Injection, Powder, For solutionIntravenous	Sagent Pharmaceuticals	25021-119	25021-0119-20

Other NDCs under ANDA 064125

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 064125
Product	Strength	Form · route	Labeler	Product NDC
Cefuroxime sodium	Cefuroxime sodium 1.5 g/20mL	Injection, Powder, For solutionIntravenous	Sagent Pharmaceuticals	25021-119